Non-Alcoholic Fatty Liver Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 30 to 75 years (or 40 to 75 years for those joining as part of the general population group)
- People who are able to give their consent to take part in the study
- People who are able to read and write in Danish
- People who have had, or currently have, a high level of alcohol use — meaning an average of at least 14 standard drinks per week for women, or 21 standard drinks per week for men, over at least 5 years; OR
- People who have metabolic syndrome, meaning excess weight around the waist plus at least two of the following: high triglycerides (a type of fat in the blood), low "good" (HDL) cholesterol, high blood pressure, or high fasting blood sugar; OR
- People who have been diagnosed with type 2 diabetes, confirmed through one or more blood sugar tests meeting specific levels (confirm with trial site for exact values)
Who may not be able to join:
- People who have signs of serious liver failure, such as fluid build-up in the abdomen, confusion caused by liver problems, yellowing of the skin or eyes, or large swollen veins in the food pipe with or without bleeding
- People who have a known liver condition other than alcohol-related liver disease or fatty liver disease (NAFLD)
- People who have cancer or another serious illness where life expectancy is less than 12 months
- People who would not be able to follow the study plan as required
- People for whom a liver tissue sample (biopsy) cannot safely be taken, if that step becomes relevant
- People who have severe liver inflammation shown by blood test results more than three times above the normal range, if a liver biopsy step is reached
- People who show signs of fluid congestion around the liver or blocked bile ducts on ultrasound, if a liver biopsy step is reached
- People whose liver stiffness measurement drops below a certain level between their initial assessment and the planned biopsy date (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Maja Thiele, MD, PhD, Professor, Department of Gastroenterology and Hepatology, Odense University Hospital
Phone: +4524998068
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Biopsy-verified advanced fibrosis; Liver-related outcomes
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.